Literature DB >> 8070441

Pharmacokinetics of fluconazole in pediatric patients.

K W Brammer1, P E Coates.   

Abstract

The pharmacokinetic properties of fluconazole were studied in more than 100 pediatric patients, including 12 premature neonates. The volume of distribution and the rate of elimination differed significantly from the values reported for adults. The volume of distribution varied with age, being greatest during the neonatal period (1.18 to 2.25 l/kg) and decreasing by young adulthood to a value similar to that reported for adults (0.7 l/kg). With the exception of neonates, fluconazole clearance was generally more rapid in children than in adults, with a mean plasma elimination half-life of just over 20 h for all pediatric age groups. In neonates, fluconazole was eliminated slowly, with a mean elimination half-life of 88.6 h at birth, 67.5 h approximately one week later and 55.2 approximately two weeks after birth. Fluconazole appeared to be well absorbed from the gastrointestinal tract. These pharmacokinetic results, taken in conjunction with the corresponding data for adults, provide a sound basis for establishing appropriate fluconazole dosage recommendations for pediatric patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8070441     DOI: 10.1007/bf01974613

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  10 in total

1.  Assay of fluconazole by high-performance liquid chromatography with a mixed-phase column.

Authors:  J E Wallace; S C Harris; J Gallegos; G Foulds; T J Chen; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

2.  The disposition and metabolism of [14C]fluconazole in humans.

Authors:  K W Brammer; A J Coakley; S G Jezequel; M H Tarbit
Journal:  Drug Metab Dispos       Date:  1991 Jul-Aug       Impact factor: 3.922

3.  Safety and pharmacokinetics of fluconazole in children with neoplastic diseases.

Authors:  J W Lee; N L Seibel; M Amantea; P Whitcomb; P A Pizzo; T J Walsh
Journal:  J Pediatr       Date:  1992-06       Impact factor: 4.406

4.  Assay of fluconazole by megabore capillary gas-liquid chromatography with nitrogen-selective detection.

Authors:  S C Harris; J E Wallace; G Foulds; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

Review 5.  Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses.

Authors:  S M Grant; S P Clissold
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

6.  Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life.

Authors:  H Saxén; K Hoppu; M Pohjavuori
Journal:  Clin Pharmacol Ther       Date:  1993-09       Impact factor: 6.875

Review 7.  Clinical pharmacokinetics of antibacterial drugs in neonates.

Authors:  C M Paap; M C Nahata
Journal:  Clin Pharmacokinet       Date:  1990-10       Impact factor: 6.447

Review 8.  Pharmacokinetics and tissue penetration of fluconazole in humans.

Authors:  K W Brammer; P R Farrow; J K Faulkner
Journal:  Rev Infect Dis       Date:  1990 Mar-Apr

9.  Fluconazole in the treatment of candidiasis in immunocompromised children.

Authors:  C Viscoli; E Castagnola; F Fioredda; B Ciravegna; G Barigione; A Terragna
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

10.  Candida albicans septicemia in a premature infant successfully treated with oral fluconazole.

Authors:  S Bodé; L Pedersen-Bjergaard; K Hjelt
Journal:  Scand J Infect Dis       Date:  1992
  10 in total
  39 in total

Review 1.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

Review 2.  Pharmacokinetics of antifungal agents in children.

Authors:  Kevin Watt; Daniel K Benjamin; Michael Cohen-Wolkowiez
Journal:  Early Hum Dev       Date:  2011-02-01       Impact factor: 2.079

3.  Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.

Authors:  D Debruyne
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

4.  Population pharmacokinetics of fluconazole in young infants.

Authors:  K C Wade; D Wu; D A Kaufman; R M Ward; D K Benjamin; J E Sullivan; N Ramey; B Jayaraman; K Hoppu; P C Adamson; M R Gastonguay; J S Barrett
Journal:  Antimicrob Agents Chemother       Date:  2008-09-22       Impact factor: 5.191

5.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

6.  Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.

Authors:  Gopal Krishna; Angela Sansone-Parsons; Monika Martinho; Bhavna Kantesaria; Lisa Pedicone
Journal:  Antimicrob Agents Chemother       Date:  2007-01-08       Impact factor: 5.191

Review 7.  Human pharmacogenomic variations and their implications for antifungal efficacy.

Authors:  Joseph Meletiadis; Stephen Chanock; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

Review 8.  Pharmacokinetics of antifungal agents in onychomycoses.

Authors:  D Debruyne; A Coquerel
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

9.  Antifungal agents in current pediatric practice.

Authors:  Cecinati Valerio; Teresa Perillo; Letizia Brescia; Fabio Giovanni Russo
Journal:  Curr Infect Dis Rep       Date:  2013-06       Impact factor: 3.725

Review 10.  Antifungal agents in neonates: issues and recommendations.

Authors:  Benito Almirante; Dolors Rodríguez
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.